Baynes Roy D. insider trades
Baynes Roy D. has filed 45 Form 4s with the SEC that we hold, for Natera, Inc. (NTRA) (Director), Travere Therapeutics, Inc. (TVTX) (Director), Nurix Therapeutics, Inc. (NRIX) (Director) and Aardvark Therapeutics, Inc. (AARD) (Director), among 6 companies in all. Across all of them we count 0 purchases worth $0 and 22 sales worth $11.3M reported on Form 4. In the last 12 months: 0 purchases ($0) and 14 sales ($5.4M). The largest single trade was a sale of 16,404 shares of Natera, Inc. worth $2.4M, dated 2024-11-15. The first filing on our record is dated 2022-05-12 and the latest 2026-08-21.
Natera, Inc. (NTRA)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2024-11-15 | S, sale reported on Form 4 | 16,404 | $2.4M | 2024-11-15 |
| 2024-11-15 | S, sale reported on Form 4 | 9,467 | $1.4M | 2024-11-15 |
| 2024-11-15 | S, sale reported on Form 4 | 1,770 | $258.9K | 2024-11-15 |
| 2024-11-15 | S, sale reported on Form 4 | 2,106 | $313.2K | 2024-11-15 |
| 2024-11-15 | S, sale reported on Form 4 | 1,983 | $297.4K | 2024-11-15 |
| 2024-11-15 | S, sale reported on Form 4 | 5,500 | $793.4K | 2024-11-15 |
| 2025-11-19 | S, sale reported on Form 4 | 1,250 | $266.8K | 2025-11-21 |
| 2025-11-19 | S, sale reported on Form 4 | 2,135 | $461.3K | 2025-11-21 |
| 2025-11-19 | S, sale reported on Form 4 | 1,727 | $370.9K | 2025-11-21 |
| 2025-11-20 | S, sale reported on Form 4 | 1,900 | $425.4K | 2025-11-21 |
| 2025-11-20 | S, sale reported on Form 4 | 1,884 | $423.7K | 2025-11-21 |
| 2025-11-20 | S, sale reported on Form 4 | 1,800 | $401.2K | 2025-11-21 |
| 2025-11-20 | S, sale reported on Form 4 | 900 | $199.6K | 2025-11-21 |
| 2025-11-20 | S, sale reported on Form 4 | 1,184 | $260.6K | 2025-11-21 |
Travere Therapeutics, Inc. (TVTX)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2025-01-23 | S, sale reported on Form 4 | 16,000 | $320.0K | 2025-01-23 |
| 2025-02-06 | S, sale reported on Form 4 | 10,000 | $220.0K | 2025-02-10 |
| 2026-04-06 | S, sale reported on Form 4 | 10,000 | $330.0K | 2026-04-07 |
| 2026-04-14 | S, sale reported on Form 4 | 26,000 | $1.1M | 2026-04-16 |
| 2026-04-14 | S, sale reported on Form 4 | 6,750 | $284.3K | 2026-04-16 |
| 2026-05-01 | S, sale reported on Form 4 | 9,750 | $431.1K | 2026-05-04 |
| 2026-05-05 | S, sale reported on Form 4 | 4,500 | $209.9K | 2026-05-06 |
| 2026-06-12 | S, sale reported on Form 4 | 4,500 | $225.0K | 2026-06-16 |
Nurix Therapeutics, Inc. (NRIX)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Aardvark Therapeutics, Inc. (AARD)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Atara Biotherapeutics, Inc. (ATRA)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Eikon Therapeutics, Inc. (EIKN)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1680739) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms